康齐祖马布:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
一种新型抗体治疗方法Concizumab在加拿大获得批准,用于使用抑制剂治疗B型血友病患者. 这标志着该患者群体在管理出血事件方面取得了重大进展.
科学领域:
- 药理学 药理学 是一个学科.
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 血友病B是一种遗传性出血障碍,是由因子IX缺乏引起的.
- 患有乙型血友病的患者,特别是那些使用抑制剂的患者,在血液管理方面面临重大挑战.
- 组织因子通路抑制剂 (TFPI) 在调节凝血级联中起着至关重要的作用.
研究的目的:
- 总结一下康齐祖马布的发展里程碑.
- 为了突出最近加拿大批准康齐祖马布治疗B型血友病与抑制剂.
- 提供关于康齐祖马布的作用机制的概述.
主要方法:
- 康齐祖马布是一种人性化的单克隆IgG4抗体,向TFPI.
- 它与TFPI的Kunitz-2域结合,抑制其与激活的X因子的相互作用.
- 开发涉及临床试验评估血友病A和B的安全性和有效性.
主要成果:
- 在临床研究中,康齐祖马布在预防或减少出血事件方面表现出有效性.
- 在2023年3月,康齐祖马布在加拿大获得批准,用于用于需要常规预防的FIX抑制剂的B型血友病患者 (≥12岁).
- 这项批准意味着针对特定的血友病B群体的新疗法选择.
结论:
- 康齐祖马布代表了B型血友病与抑制剂治疗的重大治疗进步.
- 它对TFPI的向抑制为血友病治疗提供了一种新的方法.
- 加拿大批准是使康齐祖马布为患者提供关键里程碑.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
11:09An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
Published on: April 17, 2018
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
